Prostate Cancer Roundtable

www.prostatecancerroundtable.net

P.O. Box 77476, Washington, DC 20013
www.prostatecancerroundtable.net/contact-us

Prostate Cancer Policy Agenda – 2015 - 2016

America's nationally-based prostate cancer organizations have developed a shared, national policy agenda — in the interests of the hundreds of thousands of American men who are at risk each year for a diagnosis of prostate cancer and more than 2 million men living today who have been diagnosed with this highly prevalent form of cancer.

The 2015-15 Prostate Cancer Policy Agenda:

- We continue to seek an appropriations increase to support the successful research activities of the ***Prostate Cancer Research Program*** within the Department of Defense's ***Congressionally Directed Medical Research Program*** – from its current $80 million to $120 million per year.

- We join with the broader cancer community to support increased federal appropriations for cancer research for the ***National Institutes of Health***, the ***National Cancer Institute***, and the ***Centers for Disease Control and Prevention***.

- We support an increase to $400 million per year from the current funding level of $288 million for basic and translational prostate cancer research at the ***National Cancer Institute***.

- We seek passage of a bill to create an Office on Men's Health within the Department of Health and Human Services (HHS) that can mirror the successes of the ***Office on Women's Health*** established in 1991.

- We support legislative, research, and educational efforts needed to effectively combat – and ideally to eliminate — the epidemic of prostate cancer among ***African American men***.

- We propose the establishment of a Prostate Cancer Scientific Advisory Board for the ***Office of the Chief Scientist*** at the ***U.S. Food & Drug Administration*** (FDA), with the goal of accelerating the real-time sharing of research data and the movement of new medicines into clinical practice in the best interests of patients.

- We support revisions to the decision-making processes of the ***U.S. Preventive Services Task Force (USPSTF)*** to ensure appropriate input from representatives of patient advocacy groups, specialty medical groups, and other federal agencies that have expertise in each area of preventive services under review.

- We encourage the inclusion of ***quality-of-life-related endpoints***, based on patient-reported outcomes data, in pivotal trials of all biologic and pharmaceutical agents being assessed for regulatory approval in the treatment of prostate cancer with a primary endpoint of improved survival — such that quality-of-life-related data (positive or negative) and survival data can be included in labeling for products indicated for treatment of prostate cancer when appropriate.

Effective January 1, 2015